Post image

Astrazeneca to launch new lung cancer medicine in India

Astrazeneca to launch Osimertinib Tablet 40 mg and 80 mg (Tagrisso™) in India after it received nod from Drug Controller General of India. Also stoke pricing of the company is increased by 3 % followed by this announcement.

Osimertinib 40 mg and 80 mg (Tagrisso™) is an oral anti-cancer drug for management of lung cancer. It is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy.

Read more

Dr. Reddy’s to Market and Distribute Amgen’s Repatha™ (evolocumab), Kyprolis® (carfilzomib) and BLINCYTO® (blinatumomab) in India upon Approval

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced that it has entered into a strategic collaboration with Amgen – one of the world’s leading independent biotechnology companies – to market and distribute three Amgen medicines in India in the areas of oncology and cardiology. Under the terms of the collaboration, Dr. Reddy’s shall perform a full range of regulatory and commercial services to seek approval and launch Kyprolis® (carfilzomib), BLINCYTO® (blinatumomab) and Repatha™ (evolocumab) in India. The collaboration leverages the capabilities of both companies, combining three of Amgen’s innovative therapies with Dr. Reddy’s deep understanding of patient and physician needs in India.

Read more
Post image
Post image

MSD launches blockbuster cancer drug Keytruda in India

NEW DELHI: US biopharmaceutical giant Merck, Sharpe and Dohme (MSD) has launched its blockbuster cancer drug ‘Keytruda’ (pembrolizumab) in India around a year after it first received approvals to market it, said persons aware of the development. The drug has so far only been approved here for a less prevalent type of cancer, while it is marketed in countries like the US to treat additional indications like a specific kind of lung cancer.

Keytruda, hailed as a ‘game-changer’ therapy in oncology, is expected to help the immune system identify and selectively combat only cancerous cells instead of aggressively attacking cancer cells and risking healthy tissues in the process like existing therapies. The drug generated global sales of $1.4 billion during 2016.

Read more

Channel Partner In India


  • Address:60/4, T&T House. Yusuf Sarai, New Delhi:110016
  • Phone +91-11-26532129
  • Email: IPN, New Delhi


  • Address: #308, Raheja Chambers, 12, Museum Road, Bangalore 560 001
  • Email: IPN, Bangalore


  • Address: 1/A R.G Kar Road, Shayambazar, Kolkata 700004
  • Email: IPN, Kolkata


  • Address: 203-A, 2nd Floor, Tower -11, Felix Square, IBB-2, Sushant Golf city, Lucknow 226030
  • Email: IPN, Lucknow